TRAIL shows potential cardioprotective activity

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

(2010) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

(2010) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

(2010) Steven E Lipshultz et al.   LANCET ONCOLOGY

Association of serum TRAIL level with coronary artery disease

(2010) Katsuhito Mori et al.   THROMBOSIS RESEARCH

An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction

(2009) Paola Secchiero et al.   ATHEROSCLEROSIS

Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis

(2009) Paola Secchiero et al.   CURRENT OPINION IN HEMATOLOGY

Prognostic value of apoptosis markers in advanced heart failure patients

(2009) A. Niessner et al.   EUROPEAN HEART JOURNAL

Potential Prognostic Significance of Decreased Serum Levels of TRAIL after Acute Myocardial Infarction

(2009) Paola Secchiero et al.   PLoS One